Skip to content
Research/Hormone Optimization/Human Growth Hormone (HGH/Somatropin)

Human Growth Hormone (HGH/Somatropin)

Norditropin, Humatrope, Genotropin. 191-amino acid recombinant human growth hormone. FDA-approved for GH deficiency, Turner syndrome, and HIV lipodystrophy. Used off-label for anti-aging and body composition.

Intelligence Profile

Clinical Applications

Based on the available evidence, human growth hormone (HGH/somatropin) is used clinically for several pediatric growth disorders, with emerging research in adult applications.

Primary Approved Uses

Growth Hormone Deficiency (GHD)
Recombinant human growth hormone remains the standard treatment for children with confirmed growth hormone deficiency. Recent research comparing long-acting growth hormone formulations shows therapeutic efficacy, though response rates and optimal dosing continue to be studied.

Turner Syndrome
A single-center retrospective study found that recombinant human growth hormone therapy demonstrates efficacy in children with Turner syndrome, though individual response varies based on multiple factors that require further characterization.

Idiopathic Short Stature (ISS)
Recent comparative studies indicate that children with idiopathic short stature respond differently to long-acting growth hormone therapy compared to those with confirmed growth hormone deficiency, suggesting the need for individualized treatment approaches.

Emerging Applications

Intestinal Failure
A completed Phase 4 clinical trial investigated recombinant human growth hormone for treating intestinal permeability in intestinal failure patients, representing potential expansion into gastrointestinal applications.

Safety Considerations

Recent research has identified a dose-response relationship between growth hormone treatment and scoliosis development in children with short stature, highlighting the importance of monitoring skeletal development during therapy.

Treatment Delivery

Current clinical trials are evaluating different injection pen devices for somatropin delivery to optimize patient adherence and drug bioavailability.

Disclaimer: The evidence base for some applications is limited to single studies or ongoing trials. Treatment decisions should always be made in consultation with qualified healthcare providers who can assess individual patient factors and current clinical guidelines.

Free account required

Clinical data requires a free AXIFI account to access clinical data, safety profiles, and research papers.